- In March 2024, Bayer AG announced the launch of a new generation of natural-based osmotic laxatives under its Movicol brand across key European markets including Germany, France, and the U.K. This product aims to address rising consumer demand for plant-based and gut-friendly solutions for chronic constipation, particularly among the aging population. Bayer's innovation aligns with Europe's shift toward herbal alternatives and reinforces its stronghold in the gastrointestinal therapeutics segment
- In February 2024, Sanofi introduced an over-the-counter (OTC) version of its prescription-based laxative product in select European countries. This transition follows the success of the product in the prescription market and responds to growing demand for self-care gastrointestinal remedies. The move aims to expand access to effective bowel management solutions and tap into the expanding OTC pharmaceutical segment in Europe
